Abstract. Clenbuterol [CLE: 4-amino-α(t-butyl-amino)methyl-3,5-dichlorobenzyl alcohol] is well known as a potent β 2 -adrenergic agonist and non-steroidal anabolic drug, and thus it is generally used for sports doping and asthma therapy. Although the functions of immune cells such as white blood cells (WBCs) have shown to be modulated through β 2 -adrenoceptors, the effects of CLE on immune-responsive systems have not been elucidated systematically. Therefore, the effects of CLE on the number of WBCs were studied in rats. Male adult rats were divided into CLE-administered group and the control group to compare the number of total WBCs, neutrophils, monocytes, lymphocytes, eosinophils, and basophils. The administration (dose = 1.0 mg ⋅ kg −1 body weight ⋅ day −1 , s.c.) of CLE was maintained for 30 days. CLE did not change the number of total WBCs during the experimental period. However, CLE increased significantly the number of neutrophils and monocytes, while CLE decreased drastically the number of lymphocytes and eosinophils. There was no significant change in the number of basophils between both groups. These results suggest that the administration of CLE induces drastic redistribution of WBCs in circulation without changing the number of total WBCs, and these responses of WBCs during the administration of CLE are sustained for at least 30 days.
Introduction
Doping drugs have been categorized into seven types: stimulants, analgesics, anabolic agents, diuretics, masking agents, peptide hormones and their homologues, and anti-estrogen agents (1) . Many types of drugs have been used by athletes to improve athletic performance (2) . Furthermore, many of the steroids, β 2 -agonists, growth hormones, erythropoietins, myostatin, fibroblast growth factors 1, 2, 4, 6 and 9, mechano-growth factors, and insulin-like growth factor-1 have been used as doping drugs for the improvement of athletic performances such as muscle strength, muscle power, anabolic power, and endurance (1).
It has been known for a long time that the anabolic androgenic steroids (i.e., methandienone, nandrolone, 19-norandrogen, stanozolol, and 19-norandrostendion) and the β 2 -agonists (i.e., clenbuterol, salbutamol, metaproterenol, fenoterol, and clorprenaline) heighten muscle power and muscle strength (1, 3 -9) . It is generally accepted that the anabolic drugs increase total muscle protein synthesis by the promotion of protein synthesis or decrease of proteolysis or both these actions (3, 10 -12) . These findings indicate that muscle mass and muscle power may be partly regulated at least at the gene level of muscle protein synthesis responding to anabolic drugs, although the mechanism of the actions are still unknown (3, 11) .
On the other hand, β 2 -agonists are mainly used as bronchodilators having relaxing actions on bronchial smooth muscles (13) . In addition to the bronchodilatation, β 2 -agonists have many physiological actions such as anabolic effects, lipolytic actions, glycogenolysis, vasodilatory effects, and cardiac actions (5, 8, 13) .
It is generally accepted that complex bidirectional interactions between the cells of the immune system and the nervous system contribute to additional regulatory mechanisms that influence the function of cellular activities associated with both systems (14) . It is also well known that β 2 -adrenoceptors are expressed on immune cells such as neutrophils, monocytes, T-lymphocytes, eosinophils, and mast cells (15) . For instance, β 2 -agonist has been shown to regulate the migration of neutrophils (16) and monocytes (17) . Salmeterol, a long-acting β 2 -agonist, inhibited the lipopolysaccharideinduced recruitment of neutrophils to the lung and attenuates lung inflammation (18) . However, the effects of daily anabolic dosage of various β 2 -agonists on immuno-responsive systems from the point of view of the distribution changes of the number of white blood cells (WBCs) have not been pharmacologically elucidated. In the present study, therefore, the effects of a β 2 -agonist, clenbuterol [CLE: 4-amino-α(t-butyl-amino) methyl-3,5-dichlorobenzyl alcohol], on the number of total WBCs, neutrophils, monocytes, lymphocytes, eosinophils, and basophils and visceral organ mass were studied in rats.
Materials and Methods

Experimental procedures
During the experimental period, the number of total WBCs, neutrophils, monocytes, lymphocytes, eosinophils, and basophils was analyzed according to the protocol shown in Fig. 1 . The number of red blood cells (RBCs), hemoglobin concentration, and hematocrit were also analyzed, and mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) were calculated. Thymus, spleen, adrenals, and heart were isolated and weighed on the next day after the final day of the experiment to clarify the effects of β 2 -agonist on visceral organs (Fig. 1) .
Animal care
Male 7-week-old Sprague Dawley rats (CLEA Japan, Tokyo) were pre-fed for 5 days to allow adaptation to their new environment (Fig. 1) . The rats were normally housed in cages at a controlled temperature (23°C -25°C) and a relative humidity from 50% -60%, with fixed light-dark cycles [7:00 -19 :00 (light) and 19:00 -7:00 (dark)]. Animal food (CE-2 cubic type; CLEA Japan) and once-boiled tap water were given to the rats ad libitum (19) . All rats were weighed daily during the adaptation and experimental periods. After the adaptation period, the rats were randomly divided into two groups (n = 8/ group), CLE-administered (the initial body weight = 231 ± 1 g, mean ± S.E.M.) group, and the control (CON) (the initial body weight = 231 ± 1 g, mean ± S.E.M.) group.
All experimental and animal care procedures were approved by the Committee on Animal Care and Use at Waseda University and followed the Guiding Principle for the Care and Use of Animals in the Field of Physiological Sciences established by the Physiological Society of Japan and the American Physiological Society Animal Care Guidelines. We performed procedures with the least possible pain or discomfort to the rats (20) .
Administration of CLE to rats
Clenbuterol hydrochloride (Sigma, St. Louis, MO, USA) was dissolved in 0.9% NaCl as a vehicle to obtain a CLE concentration of 1.0%. In CLE-administered group rats, CLE of 1.0 mg ⋅ kg −1 body weight ⋅ day −1 was administered from cervical portion of the back via a subcutaneous (s.c.) injection (7:30 -8:00) for 30 days (9). In CON group rats, an equivalent volume of 0.9% NaCl solution was administered to the rats instead of CLE solution in the same manner. We have studied the time course changes of plasma glucose and insulin concentrations by the administration of CLE in rats and have shown that plasma glucose and insulin concentrations were significantly increased at 0.5 -4 h from the administration of CLE (dose = 1.0 mg ⋅ kg −1 body weight ⋅ day −1 ) (21). From these results, at 2 h (9:30 -10:00) after the administration, blood samples were collected from the tail vein, and the number of WBCs, number of RBCs, hemoglobin concentration, and hematocrit were analyzed on the 0, 5th, 10th, 20th, and 30th day of the administration of CLE (Fig. 1 ). This experiment was carried out under diet-restricted feeding (food intake / rat = 20 g ⋅ day −1 ) conditions.
Blood samplings
Whole blood samples (approximately 70 µL) were collected with microcapillary tubes coated with an anticoagulant, 0.3 M EDTA-2K (ethylenediamine tetraacetic acid, dipotassium salt; Wako Pure Chemical, Osaka) from the tail vein according to the protocol (Fig. 1 ). Blood samples (50 µL each) were immediately prepared with a microsyringe and then each was diluted by 20% with cellpack (whole blood diluent for use in hematology analyzers; Sysmex, Hyogo). These samples were used for count analyses of blood cells (21) .
Count analyses of WBCs
As already reported in our previous paper, count analyses of WBCs were carried out by a fully automated hematology analyzer (Model SF-3000, Sysmex) based on a flow-cytometrical technique with light-emitting diode (21) .
Analyses of RBCs
The analyses of the number of RBCs, hemoglobin concentration, and hematocrit were also performed by the hematology analyzer. MCV, MCH, and MCHC were calculated by the following equations (22) :
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Statistical analyses Experimental data were presented as the mean ± S.E.M. The effects of CLE on the body weight and the weights of visceral organs were tested by a one-way analysis of variance (ANOVA). The effects of CLE on the number of RBCs, hemoglobin concentration, hematocrit, MCV, MCH, MCHC, and the number of WBCs were evaluated by a two-way ANOVA for repeated measures. Subsequent post hoc analyses to determine significant differences between two groups and from day 0 in each group were performed by Fisher's protected least significant difference (PLSD) test and Dunnett's test, respectively. The differences were considered significant when P was <0.05.
Results
Body weight and the weights of visceral organs
We investigated the effects of CLE on the body weight and the weights of visceral organs in rats. The body weight (402 ± 7 g) and spleen weight (908 ± 52 mg) in the CLE-administered group were comparable with those (404 ± 7 g and 882 ± 36 mg, respectively) in the CON group. However, thymus weight (390 ± 33 mg) in the CLE-administered group was 0.78 times (n.s.) relatively lower than that (500 ± 44 mg) in the CON group. Adrenal weight (70 ± 3 mg) in the CLE-administered group was 1.09 times (n.s.) relatively higher than that (65 ± 5 mg) in the CON group. Heart weight (1.30 ± 0.03 g) in the CLE-administered group was 1.10 times (P<0.05) higher than that (1.19 ± 0.02 g) in the CON group.
The number of RBCs, hemoglobin concentration, and hematocrit
As shown in Fig. 2A , the number of RBCs in the CLE-administered group was 0.83 (P<0.001), 0.88 (P<0.001), 0.89 (P<0.001), and 0.89 times (P<0.001) lower than that in the CON group on the 5th, 10th, 20th, and 30th day of CLE administration, respectively. Similar patterns were clearly observed in the hemoglobin concentration and hematocrit (Fig. 2: B and C,  respectively) .
On the other hand, no differences of MCV, MCH, and MCHC between both groups were observed during the experimental period (Fig. 2: D, E, and F, respectively). Plasma fluid volume has been shown to be increased by the administration of CLE (21) . Also, it has not been reported that β 2 -agonists affect erythropoiesis. These results suggest that the administration of CLE to rats induces the expansion of extracellular fluid volume without affecting RBC levels. Therefore, in the present study, the number of WBCs was corrected by the corresponding hematocrit values (22, 23) .
The number of total WBCs, neutrophils, and monocytes
Next we studied the effects of CLE on the number of total WBCs, neutrophils, monocytes, lymphocytes, eosinophils, and basophils during the experimental period. These results are shown in Fig. 3 . As shown in Fig. 3A , no significant difference of the number of total WBCs between both groups was observed during the experimental period. However, the number of neutrophils in the CLE-administered group was 1.62 (P<0.05), 1.50 (P<0.05), 1.81 (P<0.05), and 1.22 times (n.s.) higher than that in the CON group on the 5th, 10th, 20th, and 30th day of CLE administration, respectively (Fig. 3B) . The number of monocytes in the CLE-administered group was also 1.63 (P<0.01), 1.56 (n.s.), 1.80 (P<0.001), and 1.89 times (P<0.05) higher than that in CON group on the 5th, 10th, 20th, and 30th day of CLE administration, respectively (Fig. 3C) .
The number of lymphocytes, eosinophils, and basophils
As shown in Fig. 3D , the number of lymphocytes in the CLE-administered group was 0.57 (P<0.001), 0.54 (P<0.001), 0.53 (P<0.001), and 0.55 times (P<0.001) drastically lower than that in the CON group on the 5th, 10th, 20th, and 30th day of CLE administration, respectively. On the other hand, the number of eosinophils in the 10th, 20th, and 30th day in the CON group was 2.12 (P<0.05), 1.98 (n.s.), and 2.38 times (P<0.01) higher than that on 0th day (Fig. 3E) . However, since the number of eosinophils in the CLE-administered group was constant during the experimental period, the number of eosinophils in the CLE-administered group was also 0.86 (n.s.), 0.53 (P<0.01), 0.62 (P<0.05), and 0.50 times (P<0.05) lower than that in the CON group on the 5th, 10th, 20th, and 30th day of CLE administration, respectively (Fig. 3E) . Although the number of basophils in the CLE-administered group was relatively lower than that in the CON group during the experimental period, no significant changes were observed between both groups (Fig. 3F) . 
Discussion
The purpose of the present study was to elucidate the effects of administration of the β 2 -agonist clenbuterol (CLE) (dose = 1.0 mg ⋅ kg −1 body weight ⋅ day
) for 30 days on the number of total WBCs, neutrophils, monocytes, lymphocytes, eosinophils, and basophils in male adult rats. The main findings of the present study are summarized as follows: 1) The administration of CLE did not affect significantly the number of total WBCs (Fig. 3A) and basophils (Fig. 3F) during the experimental period. 2) However, the administration of CLE clearly increased the number of neutrophils (Fig. 3B) and monocytes (Fig. 3C). 3) On the contrary, the administration of CLE drastically decreased the number of lymphocytes (Fig. 3D) and eosinophils (Fig. 3E) . These results suggest that the administration of CLE induces drastic redistribution of WBCs in circulation without changing the number of total WBCs, and these responses of WBCs during the administration period of CLE are at least sustained for 30 days.
CLE administration-induced changes of visceral organ weights
The present study showed that the administration of CLE for 30 days decreased relatively the weight of the thymus, one of the central lymphoid organs. On the contrary, the administration of CLE increased relatively the weight of the adrenals and increased markedly the weight of the heart. However, no differences in the weight of the spleen, one of the peripheral lymphoid organs, were observed in both groups. These results suggest that the administration of CLE induced mild stress responses during the experimental period.
Blanco et al. (24) reported that anabolic dosage of CLE induced apoptotic cell death in thymocytes in pigs. According to McConkey et al. (25) , agents that elevate intracellular cyclic adenosine monophosphate (cAMP) concentration stimulated DNA fragmentation or apoptotic cell death in thymocytes. Since CLE specifically binds to the β 2 -adrenergic receptor, a G proteincoupled receptor and then activates the heterotrimeric G protein -adenylate cyclase -cAMP productive pathway, CLE would induce directly apoptotic cell death in thymocytes, which would cause the reduction of thymus mass, although there was no significant difference between both groups in the present study. Furthermore, Illera et al. (26) showed that anabolic dosage of CLE caused adrenal gland hypertrophy and increased secretions of glucocorticoids such as corticosterone and cortisol in rats. Thus, CLE administration-induced reduction of thymus mass would be partially caused by glucocorticoid-induced apoptotic cell death in thymocytes. It is well known that glucocorticoids are adrenal steroid hormones with anti-inflammatory actions and induce immature T lymphocyte and thymus cell apoptosis (25, 27) . On the contrary, the reactivity of peripheral lymphocytes in the spleen against CLE may be relatively lower than that of thymocytes. As already described, CLE administration-induced adrenal and heart hypertrophy would be caused by stress-induced activation of the hypothalamo-hypophyseal-adrenocortical axis stimulated by the β 2 -adrenergic signal transduction cascade (28, 29) . Therefore, the physiological defense system via the endocrine system may be at least in part activated by the administration of CLE.
CLE administration-induced distribution changes of WBCs
The present study demonstrated clearly that the administration of CLE did not change the number of total WBCs during the experimental period (Fig. 3A) . However, as reported in our recent paper (22) , prolonged inactivity such as immobilization and whole body suspension increased markedly the number of total WBCs. Therefore, response properties of various WBCs are clearly different between the administration of CLE and prolonged inactivity.
It is well known that β 2 -adrenoceptors are expressed on immune cells such as neutrophils, monocytes, Tlymphocytes, eosinophils, and mast cells, implicated in the pathophysiology of respiratory disease (15) . However, the distribution changes of WBCs such as neutrophils, monocytes, lymphocytes, eosinophils, and basophils in circulation by β 2 -agonists have not been reported. The present study demonstrated that the administration of CLE significantly increased the circulating number of phagocytes such as neutrophils (Fig. 3B) and monocytes (Fig. 3C) . These neutrophilia and monocytosis are also known to be induced by exhausting exercises in humans (30, 31) . Recently, we also demonstrated that prolonged inactivity [hypokinesia (i.e., decreased motor activity) / hypodynamia (i.e., decreased mechanical loading)] increased significantly the number of neutrophils and monocytes (22) . These results indicate that neutrophilia and monocytosis are some of the general adaptation reactions against various endogenous stimuli and are likely to play fundamental roles in the physiological defense system in the living body.
On the other hand, glucocorticoids and / or the hematopoietic cytokine interleukin-6 are known to induce the mobilization of neutrophils from the bone marrow into the circulating blood (32, 33) , inhibit apoptosis of the circulating neutrophils (34), and inhibit migration of neutrophils into the tissues (32, 35) . Other hematopoietic cytokines such as granulocyte colonystimulating factor (G-CSF) and macrophage colonystimulating factor (M-CSF) have been known for a long time to induce the differentiation of hematopoietic cells to neutrophils and monocytes (36 -38) . However, catecholamines are also known to induce the mobilization of neutrophils from the margin of a vessel into the circulating blood by the arterial shearing force through β-adrenergic enhancement of heart functions (39), which would be a cause of neutrophilia and monocytosis during the administration of CLE, because CLE is a potent β 2 -agonist.
van Furth and Cohen (40) studied the distribution of monocytes in mice and reported that the circulating monocytes account for 40% and the marginated monocytes account for 60% of the peripheral blood monocytes. These findings suggest that the circulating number of monocytes is capable of being increased up to 2.5 times when all of the marginated monocytes are mobilized into the circulating blood. In the present study, the circulating number of monocytes in CLEadministered group was increased to 1.56 -1.89 times compared to that in CON group during the experimental period (Fig. 3C) , suggesting that CLE-induced monocytosis might be mediated mainly by the mobilization from the vessel margin.
As shown in the present paper, the administration of CLE decreased drastically the circulating number of lymphocytes to about 0.5 times on the 5th to 30th day (Fig. 3D ). This lymphocytopenia would cancel the increment of the circulating number of total WBCs accompanied by neutrophilia and monocytosis (Fig. 3 : B and C). Cioca et al. (41) reported that peripheral lymphocytes were led to apoptosis by catecholamines like dopamine or dobutamine, whose apoptotic effect was completely or partially blocked by the β-receptor antagonist propranolol, respectively, indicating that pharmacological dosage of β 2 -agonist would induce apoptosis in a great number of lymphocytes in the circulating blood, followed by drastic reduction of their number in the present study (Fig. 3D) . On the other hand, it is also conceivable that lymphocytopenia induced by the administration of CLE is a reversible phenomenon because the decreasing rate of the number of lymphocytes remains almost constant (43% -47%) during the experimental period (Fig. 3D) .
Although it is unclear why the number of eosinophils in the CON group was significantly increased from the 0th day during the experimental period, our data show that CLE-administration inhibited the mobilization of eosinophils into the circulating blood (Fig. 3E) , and there was no significant change in the number of basophils between both groups during the experimental period (Fig. 3F) . However, according to our recent data, prolonged inactivity conditions increased the circulating number of eosinophils and basophils (22) . These results suggest that mechanisms of redistribution of eosinophils and basophils are different from those of the neutrophils and monocytes under these experimental conditions, indicating that physiological significances of eosinophils and basophils during various endogenous stimuli would be different from those of other granulocytes. For example, glucocorticoids are reported to enhance eosinophil apoptosis but inhibit neutrophil apoptosis in rats (42) . Although the administration of CLE induces β-adrenergic promotion of arterial shearing force, the circulating number of eosinophils clearly decreased. β-Adrenergic stimuli would induce the removals of eosinophils and basophils from the circulating blood ( Fig. 3 : E and F, respectively). Possible mechanisms of CLE-induced suppression of the mobilization of eosinophils into blood are still uncertain.
